New Findings on Aclarubicin in the Treatment of Acute Myeloid Leukemia

W. Hiddemann, R. Mertelsmann (Herausgeber)

Buch | Softcover

IX, 52 Seiten

1990
Springer Berlin (Verlag)
978-3-540-52613-1 (ISBN)

Artikel merken

Since the introduction of new anthracycline derivatives and anthrachi none analogues a few years ago, aclacinomycin A (Aclarubicin) has become an established agent for the treatment of hematologic malig nancies. A special symposium was therefore held during the congress of the German Society of Hermatology and Oncology in Hannover in October 1989 to provide an up-to-date overv.iew. Leading experts from the United States, Sweden, and Germany reported on the results being obtained with aclacinomycin A, alone or combined with other agents, in patients with acute leukemias and myelodysplastic syndromes. This book is based on their contributions. As regards single-agent treatment, aclacinomycin A in myelodys plastic syndromes is dealt with, as well as its application in older patients with acute myeloid leukemia. Four contributions are devoted to the use of aclacinomycin A in combination with conventional or intermediate dose cytosine arabinoside or etoposide in patients with relapsed or refractory acute myeloid leukemia. The results reported indicate that aclacinomycin A has substantial activity in the treatment of hematologic malignancies. In summary, this book provides a valuable update on the current status of aclacinomycin A as used by experts in the treatment of he matologic malignancies.

In light of the development of new anthracycline derivatives or anthrachinone derivatives, this book provides indispensable information about the current status of aclacinomycin A for the treatment of hematologic malignancies, and is thus of great interest to hemato-on cologists.

Aclarubicin in Single Agent and Combined Chemotherapy of Adult Acute Myeloid Leukemia.- Low-Dose Aclacinomycin and Intermediate-Dose Cytosine - Arabinoside in Relapsed and Refractory Acute Myelogenous Leukemia.- Aclarubicin Plus Cytosine Arabinoside Versus Daunorubicin Plus Cytosine Arabinoside in De Novo Acute Myelocytic Leukemia: A Danish National Trial.- Fractionated Aclacinomycin in Combination with Cytosine Arabinoside and Etoposide for Remission Induction in Adult Acute Myeloid Leukemia.- Aclarubicin in the Treatment of Refractory Acute Leukemias.- Aclacinomycin A/Etoposide Combination Therapy for Advanced Relapsed Acute Myeloid Leukemia: Results of a Pilot Study of the Arbeitsgemeinschaft Internistische Onkologie.- Low-Dose Aclacinomycin A in Myelodysplastic Syndromes and Subsequent Acute Myelogenous Leukemia: A Phase II Study.

Erscheint lt. Verlag	22.8.1990
Zusatzinfo	IX, 52 p.
Verlagsort	Berlin
Sprache	englisch
Maße	155 x 235 mm
Gewicht	140 g
Themenwelt	Medizinische Fachgebiete ► Innere Medizin ► Hämatologie
Themenwelt	Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
Schlagworte	Aclacinomycin A • Akute Leukämie • Myelodysplast • Onkologie • Syndrom
ISBN-10	3-540-52613-7 / 3540526137
ISBN-13	978-3-540-52613-1 / 9783540526131
Zustand	Neuware